Brain inflammation enhances 1-methyl-4-phenylpyridinium-evoked neurotoxicity in rats
Identifieur interne : 000895 ( PascalFrancis/Checkpoint ); précédent : 000894; suivant : 000896Brain inflammation enhances 1-methyl-4-phenylpyridinium-evoked neurotoxicity in rats
Auteurs : Kerry B. Goralski [Canada] ; Kenneth W. Renton [Canada]Source :
- Toxicology and applied pharmacology [ 0041-008X ] ; 2004.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
Experimental Parkinson's disease and Parkinson's disease in humans include a CNS inflammatory component that may contribute to the pathogenesis of the disease. CNS inflammation produces a loss in cytochrome P450 metabolism and may impair the brain's protection against neurotoxins. We have examined if preexisting inflammation in the brain could increase the toxicity of the dopaminergic toxin 1-methyl-4-phenylpyridinium (MPP+). Lipopolysaccharide (LPS, 25 μg) or saline (control) was injected into the left lateral cerebral ventricle. A single injection of MPP+ into the median forebrain bundle followed 48 h later and produced a reduction in striatal dopamine content that was dose and time dependant. Two-days after 5 μg of MPP+ was administered, a 90% decrease in striatal dopamine content was observed in saline- and LPS-pretreated rats. However, 4 and 7 days after 5 μg MPP+ treatment, striatal dopamine recovered up to 70-80% of control values in saline-pretreated rats but remained depressed (80-90%) in rats treated with LPS. These results suggested that CNS inflammation might create an increased risk factor for drug-induced CNS toxicity or chemically mediated Parkinson's disease. The prolonged toxicity of MPP+ may be due to a decrease in brain cytochrome P450 metabolism that occurs during inflammation. As a second objective for the study, we examined if the CNS lesion produced by MPP+ altered cytochrome P450 metabolic activity in the liver, kidney, and lung. We have demonstrated a novel mechanism whereby the brain pathology produced by MPP+ treatment contributes to a reduction in cytochrome P450 metabolism in the kidney but not the liver or lung. Therefore, a chemically evoked CNS disorder with a chronic inflammatory component might have major effects on the renal metabolism of drugs or endogenous substrates.
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
Pascal:04-0457869Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Brain inflammation enhances 1-methyl-4-phenylpyridinium-evoked neurotoxicity in rats</title><author><name sortKey="Goralski, Kerry B" sort="Goralski, Kerry B" uniqKey="Goralski K" first="Kerry B." last="Goralski">Kerry B. Goralski</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Pharmacology, Dalhousie University</s1><s2>Halifax, Nova Scotia, B3H 1X5</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Halifax, Nova Scotia, B3H 1X5</wicri:noRegion></affiliation></author><author><name sortKey="Renton, Kenneth W" sort="Renton, Kenneth W" uniqKey="Renton K" first="Kenneth W." last="Renton">Kenneth W. Renton</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Pharmacology, Dalhousie University</s1><s2>Halifax, Nova Scotia, B3H 1X5</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Halifax, Nova Scotia, B3H 1X5</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">04-0457869</idno><date when="2004">2004</date><idno type="stanalyst">PASCAL 04-0457869 INIST</idno><idno type="RBID">Pascal:04-0457869</idno><idno type="wicri:Area/PascalFrancis/Corpus">000970</idno><idno type="wicri:Area/PascalFrancis/Curation">000353</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000895</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000895</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Brain inflammation enhances 1-methyl-4-phenylpyridinium-evoked neurotoxicity in rats</title><author><name sortKey="Goralski, Kerry B" sort="Goralski, Kerry B" uniqKey="Goralski K" first="Kerry B." last="Goralski">Kerry B. Goralski</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Pharmacology, Dalhousie University</s1><s2>Halifax, Nova Scotia, B3H 1X5</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Halifax, Nova Scotia, B3H 1X5</wicri:noRegion></affiliation></author><author><name sortKey="Renton, Kenneth W" sort="Renton, Kenneth W" uniqKey="Renton K" first="Kenneth W." last="Renton">Kenneth W. Renton</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Pharmacology, Dalhousie University</s1><s2>Halifax, Nova Scotia, B3H 1X5</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Halifax, Nova Scotia, B3H 1X5</wicri:noRegion></affiliation></author></analytic><series><title level="j" type="main">Toxicology and applied pharmacology</title><title level="j" type="abbreviated">Toxicol. appl. pharmacol.</title><idno type="ISSN">0041-008X</idno><imprint><date when="2004">2004</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Toxicology and applied pharmacology</title><title level="j" type="abbreviated">Toxicol. appl. pharmacol.</title><idno type="ISSN">0041-008X</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animal</term><term>Basal ganglion</term><term>Cytochrome P450</term><term>Inflammation</term><term>Kidney</term><term>Lipopolysaccharide</term><term>Liver</term><term>Nervous system diseases</term><term>Parkinson disease</term><term>Rat</term><term>Toxicity</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Inflammation</term><term>Parkinson maladie</term><term>Toxicité</term><term>Système nerveux pathologie</term><term>Animal</term><term>Rat</term><term>Cytochrome P450</term><term>Lipopolyoside</term><term>Noyau gris central</term><term>Rein</term><term>Foie</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Experimental Parkinson's disease and Parkinson's disease in humans include a CNS inflammatory component that may contribute to the pathogenesis of the disease. CNS inflammation produces a loss in cytochrome P450 metabolism and may impair the brain's protection against neurotoxins. We have examined if preexisting inflammation in the brain could increase the toxicity of the dopaminergic toxin 1-methyl-4-phenylpyridinium (MPP<sup>+</sup>). Lipopolysaccharide (LPS, 25 μg) or saline (control) was injected into the left lateral cerebral ventricle. A single injection of MPP<sup>+</sup> into the median forebrain bundle followed 48 h later and produced a reduction in striatal dopamine content that was dose and time dependant. Two-days after 5 μg of MPP<sup>+</sup> was administered, a 90% decrease in striatal dopamine content was observed in saline- and LPS-pretreated rats. However, 4 and 7 days after 5 μg MPP<sup>+</sup> treatment, striatal dopamine recovered up to 70-80% of control values in saline-pretreated rats but remained depressed (80-90%) in rats treated with LPS. These results suggested that CNS inflammation might create an increased risk factor for drug-induced CNS toxicity or chemically mediated Parkinson's disease. The prolonged toxicity of MPP<sup>+</sup> may be due to a decrease in brain cytochrome P450 metabolism that occurs during inflammation. As a second objective for the study, we examined if the CNS lesion produced by MPP<sup>+</sup> altered cytochrome P450 metabolic activity in the liver, kidney, and lung. We have demonstrated a novel mechanism whereby the brain pathology produced by MPP<sup>+</sup> treatment contributes to a reduction in cytochrome P450 metabolism in the kidney but not the liver or lung. Therefore, a chemically evoked CNS disorder with a chronic inflammatory component might have major effects on the renal metabolism of drugs or endogenous substrates.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0041-008X</s0></fA01><fA02 i1="01"><s0>TXAPA9</s0></fA02><fA03 i2="1"><s0>Toxicol. appl. pharmacol.</s0></fA03><fA05><s2>196</s2></fA05><fA06><s2>3</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Brain inflammation enhances 1-methyl-4-phenylpyridinium-evoked neurotoxicity in rats</s1></fA08><fA11 i1="01" i2="1"><s1>GORALSKI (Kerry B.)</s1></fA11><fA11 i1="02" i2="1"><s1>RENTON (Kenneth W.)</s1></fA11><fA14 i1="01"><s1>Department of Pharmacology, Dalhousie University</s1><s2>Halifax, Nova Scotia, B3H 1X5</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></fA14><fA20><s1>381-389</s1></fA20><fA21><s1>2004</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>9067</s2><s5>354000113916050070</s5></fA43><fA44><s0>0000</s0><s1>© 2004 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>1 p.1/4</s0></fA45><fA47 i1="01" i2="1"><s0>04-0457869</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>Toxicology and applied pharmacology</s0></fA64><fA66 i1="01"><s0>USA</s0></fA66><fC01 i1="01" l="ENG"><s0>Experimental Parkinson's disease and Parkinson's disease in humans include a CNS inflammatory component that may contribute to the pathogenesis of the disease. CNS inflammation produces a loss in cytochrome P450 metabolism and may impair the brain's protection against neurotoxins. We have examined if preexisting inflammation in the brain could increase the toxicity of the dopaminergic toxin 1-methyl-4-phenylpyridinium (MPP<sup>+</sup>). Lipopolysaccharide (LPS, 25 μg) or saline (control) was injected into the left lateral cerebral ventricle. A single injection of MPP<sup>+</sup> into the median forebrain bundle followed 48 h later and produced a reduction in striatal dopamine content that was dose and time dependant. Two-days after 5 μg of MPP<sup>+</sup> was administered, a 90% decrease in striatal dopamine content was observed in saline- and LPS-pretreated rats. However, 4 and 7 days after 5 μg MPP<sup>+</sup> treatment, striatal dopamine recovered up to 70-80% of control values in saline-pretreated rats but remained depressed (80-90%) in rats treated with LPS. These results suggested that CNS inflammation might create an increased risk factor for drug-induced CNS toxicity or chemically mediated Parkinson's disease. The prolonged toxicity of MPP<sup>+</sup> may be due to a decrease in brain cytochrome P450 metabolism that occurs during inflammation. As a second objective for the study, we examined if the CNS lesion produced by MPP<sup>+</sup> altered cytochrome P450 metabolic activity in the liver, kidney, and lung. We have demonstrated a novel mechanism whereby the brain pathology produced by MPP<sup>+</sup> treatment contributes to a reduction in cytochrome P450 metabolism in the kidney but not the liver or lung. Therefore, a chemically evoked CNS disorder with a chronic inflammatory component might have major effects on the renal metabolism of drugs or endogenous substrates.</s0></fC01><fC02 i1="01" i2="X"><s0>002B03</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Inflammation</s0><s5>07</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Inflammation</s0><s5>07</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Inflamación</s0><s5>07</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Parkinson maladie</s0><s5>10</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Parkinson disease</s0><s5>10</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Parkinson enfermedad</s0><s5>10</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Toxicité</s0><s5>11</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Toxicity</s0><s5>11</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Toxicidad</s0><s5>11</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Système nerveux pathologie</s0><s5>12</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Nervous system diseases</s0><s5>12</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Sistema nervioso patología</s0><s5>12</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Animal</s0><s5>14</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Animal</s0><s5>14</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Animal</s0><s5>14</s5></fC03><fC03 i1="06" i2="X" l="FRE"><s0>Rat</s0><s5>15</s5></fC03><fC03 i1="06" i2="X" l="ENG"><s0>Rat</s0><s5>15</s5></fC03><fC03 i1="06" i2="X" l="SPA"><s0>Rata</s0><s5>15</s5></fC03><fC03 i1="07" i2="X" l="FRE"><s0>Cytochrome P450</s0><s5>16</s5></fC03><fC03 i1="07" i2="X" l="ENG"><s0>Cytochrome P450</s0><s5>16</s5></fC03><fC03 i1="07" i2="X" l="SPA"><s0>Citocromo P450</s0><s5>16</s5></fC03><fC03 i1="08" i2="X" l="FRE"><s0>Lipopolyoside</s0><s5>17</s5></fC03><fC03 i1="08" i2="X" l="ENG"><s0>Lipopolysaccharide</s0><s5>17</s5></fC03><fC03 i1="08" i2="X" l="SPA"><s0>Lipopoliósido</s0><s5>17</s5></fC03><fC03 i1="09" i2="X" l="FRE"><s0>Noyau gris central</s0><s5>18</s5></fC03><fC03 i1="09" i2="X" l="ENG"><s0>Basal ganglion</s0><s5>18</s5></fC03><fC03 i1="09" i2="X" l="SPA"><s0>Núcleo basal</s0><s5>18</s5></fC03><fC03 i1="10" i2="X" l="FRE"><s0>Rein</s0><s5>19</s5></fC03><fC03 i1="10" i2="X" l="ENG"><s0>Kidney</s0><s5>19</s5></fC03><fC03 i1="10" i2="X" l="SPA"><s0>Riñón</s0><s5>19</s5></fC03><fC03 i1="11" i2="X" l="FRE"><s0>Foie</s0><s5>20</s5></fC03><fC03 i1="11" i2="X" l="ENG"><s0>Liver</s0><s5>20</s5></fC03><fC03 i1="11" i2="X" l="SPA"><s0>Hígado</s0><s5>20</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Rodentia</s0><s2>NS</s2></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Rodentia</s0><s2>NS</s2></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Rodentia</s0><s2>NS</s2></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Mammalia</s0><s2>NS</s2></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Mammalia</s0><s2>NS</s2></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Mammalia</s0><s2>NS</s2></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Vertebrata</s0><s2>NS</s2></fC07><fC07 i1="03" i2="X" l="ENG"><s0>Vertebrata</s0><s2>NS</s2></fC07><fC07 i1="03" i2="X" l="SPA"><s0>Vertebrata</s0><s2>NS</s2></fC07><fC07 i1="04" i2="X" l="FRE"><s0>Encéphale pathologie</s0><s5>37</s5></fC07><fC07 i1="04" i2="X" l="ENG"><s0>Cerebral disorder</s0><s5>37</s5></fC07><fC07 i1="04" i2="X" l="SPA"><s0>Encéfalo patología</s0><s5>37</s5></fC07><fC07 i1="05" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0><s5>38</s5></fC07><fC07 i1="05" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0><s5>38</s5></fC07><fC07 i1="05" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0><s5>38</s5></fC07><fC07 i1="06" i2="X" l="FRE"><s0>Maladie dégénérative</s0><s5>39</s5></fC07><fC07 i1="06" i2="X" l="ENG"><s0>Degenerative disease</s0><s5>39</s5></fC07><fC07 i1="06" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0><s5>39</s5></fC07><fC07 i1="07" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0><s5>40</s5></fC07><fC07 i1="07" i2="X" l="ENG"><s0>Central nervous system disease</s0><s5>40</s5></fC07><fC07 i1="07" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0><s5>40</s5></fC07><fN21><s1>257</s1></fN21><fN44 i1="01"><s1>OTO</s1></fN44><fN82><s1>OTO</s1></fN82></pA></standard></inist><affiliations><list><country><li>Canada</li></country></list><tree><country name="Canada"><noRegion><name sortKey="Goralski, Kerry B" sort="Goralski, Kerry B" uniqKey="Goralski K" first="Kerry B." last="Goralski">Kerry B. Goralski</name></noRegion><name sortKey="Renton, Kenneth W" sort="Renton, Kenneth W" uniqKey="Renton K" first="Kenneth W." last="Renton">Kenneth W. Renton</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PascalFrancis/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000895 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/biblio.hfd -nk 000895 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= PascalFrancis
|étape= Checkpoint
|type= RBID
|clé= Pascal:04-0457869
|texte= Brain inflammation enhances 1-methyl-4-phenylpyridinium-evoked neurotoxicity in rats
}}
| This area was generated with Dilib version V0.6.29. |  |